BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 01/13/22

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders...

Cantor Fitzgerald has started the coverage on Brooklyn ImmunoTherapeutics (BTX -2.9%) with an Overweight recommendation arguing that the company could attract a partnership for its experimental cancer therapy IRX-2. IRX‑2, a mixed, human-derived cytokine product, is currently undergoin...

NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, ...

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) jumps 3.58% pre-market on being added to the Nasdaq Biotech Index, effective December 20, 2021. Brooklyn joins 128 other companies on the index, as 21 companies were removed. For further details see: Brooklyn Immunotherap...

NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, ...

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, ...

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, ...

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) has filed with the SEC a registration statement on Form S-1 relating to the proposed public offering of up to 6,281,454 shares of common stock by certain selling stockholders in connection with its acquisition of Novellus in July 2021. Shares down...

NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange Commission a registration statement on Form S-1 relating to the proposed public offering...

Brooklyn Immunotherapeutics (NASDAQ:BTX): Q3 GAAP EPS of -$1.70 misses by $1.62. Cash of $24.4M. Press Release For further details see: Brooklyn Immunotherapeutics EPS misses by $1.62